• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Canada
  • United Kingdom
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences
Home > Financial Services > Want a fuller picture of biotech’s promise? Look beyond the public markets

Want a fuller picture of biotech’s promise? Look beyond the public markets

Jun. 19, 2019 by Matt Wolf

  • email
  • Twitter
  • Facebook
  • Linkedin

A recent Wall Street Journal article highlights the underperformance of the Nasdaq Biotech Index against other benchmarks. The article implies the weak returns are due to a lack of blockbuster biotech therapies; at the same time, the piece underscores the robust private funding activity within the biotech ecosystem. The ecosystem and the capital markets in which it operates are complex; viewing this sector through the lens of the public markets doesn’t provide a complete picture of its promise to investors.

The ecosystem and the capital markets in which it operates are complex; viewing this sector through the lens of the public markets doesn’t provide a complete picture of its promise to investors.

It is true that biotech and pharma companies are moving toward developing diverse portfolios of therapies and away from relying on blockbuster drugs. However, the WSJ article does not explore that perhaps biotech returns, as measured by the Nasdaq index, are falling because more and more investor activity is occurring in private markets, rather than on public exchanges.

Based on our discussions with clients and investors, many early-stage biotech companies choose to remain private because it is expensive to go public and remain that way. Furthermore, venture capital firms raised a record amount of dry powder in 2018: $55 billion, according to data from research firm Pitchbook.

Investors who want exposure to biotech are increasingly turning to startup, venture and private equity funds for opportunities. Private biotech investment volume grew a staggering 71.8 percent in 2018, according to Pitchbook data. Deal volume, while not quite as robust this year, is on track to exceed that of 2017 by nearly 50 percent.

If we look at transaction counts and volume side by side, the picture becomes clear: Growth in private capital raising has outpaced public deals. And, as more biotech companies remain private, the Nasdaq benchmark becomes less reliable as a gauge of sector performance.

Median post-money valuations in private biotech have increased 86 percent since 2014, according to Pitchbook. The median pre-money valuation has increased even more, more than doubling in the same period.

We can’t overstate the complexity of the ecosystem. The robust private funding market for biotech and pharma may surely have something to do with lagging public returns in the sector.

  • email
  • Twitter
  • Facebook
  • Linkedin

Related posts

  • Public scrutiny over ESG holdings will cause universal reporting change

    As environmental, social and governance investing continues to grow in popularity, investors need to carefully evaluate how their holdings will be viewed by the public. Asset managers must balance their desire to promote ESG consciousness with their fiduciary…

Filed Under: Financial Services, Health Care, Life Sciences

About Matt Wolf

@MattWolfHC

Matt leads RSM’s health care valuation consulting group. In this capacity, Matt helps health care clients evaluate mergers, acquisitions, joint ventures, and other growth strategies.

In January 2018, Matt was selected as a senior analyst RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves. These senior analysts advise clients on conditions impacting middle market leaders. Matt’s focus is the health care and life sciences space.

Primary Sidebar

Other Regions

  • Canada
  • United Kingdom

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent Health Care articles

5 things to know in life sciences: Week of Feb. 22

Feb. 26, 2021

Pandemic highlights the need for better use of data among health care providers

Feb. 24, 2021

CHART OF THE DAY: State disparity in mental health preparedness

Feb. 19, 2021

Recent Life Science articles

5 things to know in life sciences: Week of March 1

Mar. 4, 2021

5 things to know in life sciences: Week of Feb. 22

Feb. 26, 2021

5 things to know in life sciences: Week of Feb. 15

Feb. 19, 2021

Recent Finance articles

Low interest rates offer private equity firms a rare opportunity to invest

Feb. 25, 2021

CHART OF THE DAY: ESG comes to financial services

Feb. 25, 2021

Private equity and venture capital stay resilient in the EU and UK

Feb. 17, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences